June 17th IPIX PR: "Testing results observed to date formed the basis for a federal grant application that was submitted last week by the RBL, in collaboration with the Company, proposing to evaluate Brilacidin’s potential as a pan-coronavirus therapeutic, with possible extension into other viruses."
June 11th IPIX PR: "The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing. Longer-term objectives include potentially performing additional research to develop Brilacidin as a broad-spectrum antiviral, with possible application beyond coronaviruses, e.g., treating other viruses, such as encephalitic alphaviruses and filoviruses."
It's all in the PR's
We are all anxiously awaiting the RBL grant news as it relates to the RBL collaboration. Other than the Feb BARDA announcement, has IPIX said anything about getting grant money for themselves? CTAP news on deck
News 
Market Data 
Discover 
